Objective-To determine the persistence of antibody to diphtheria, tetanus, and pertussis in children receiving an accelerated schedule of primary immunisation.
Introduction
In May 1990 the Department of Health introduced an accelerated schedule of primary immunisation. The ages at which children receive combined diphtheria/ tetanus/pertussis vaccine (triple vaccine) and oral polio vaccine were changed from 3, 4-512, and 8½1/2-l months'2 to 2, 3, and 4 months.3 No further doses are recommended until the diphtheria/tetanus and polio booster at 41/2-5 years of age.
There is evidence that accelerated immunisation provides an adequate immediate immune response,4-7 but concern has been raised about the persistence of such immunity.' For this reason when an accelerated schedule was recommended during periods of high incidence of whooping cough it was followed by a reinforcing dose of diphtheria/tetanus and polio vaccines at 12-18 nonths of age.2
Plymouth Health Authority employed an accelerated schedule of triple vaccine given at 3, 4, and 5 months followed by a diphtheria/tetanus booster at 18 protection (001lU/mI).'2 Table I shows the distribution of antitoxin concentrations. Children who had low antitoxin concentrations (<O 1OIU/ml) were not clustered in any one group. Antitoxin concentrations were highest in children who had received the 18 month diphtheria/tetanus booster, significantly higher than those in children who had received three doses of triple vaccine before the age of 6 months without a subsequent booster (p<0-001). Among children who did not receive the diphtheria/ tetanus booster, there was no significant difference in antitoxin concentration between those who received their third dose of triple vaccine before 6 months of age compared with those who received this third dose between 8 and 13 months of age (table II) . Concentrations of tetanus antitoxin, however, were significantly higher in children who received their third dose of triple vaccine before 6 months of age than in those who received it between 6 and 7 months of age (p= 0-01).
There was no significant difference in geometric mean titres for each pertussis antibody between children who received their third dose of triple vaccine below age 6 months compared with those receiving this third dose between 8 and 13 months of age. For all three pertussis antibodies there was an increase in the geometric mean titre with age at the third dose of the pertussis vaccine, but no significant trend was found (table III) .
Discussion
This study provides evidence that a 3, 4, 5 month schedule of immunisation with triple vaccine provides adequate protection against diphtheria, tetanus, and whooping cough until the age of the preschool booster. Combined diphtheria/tetanus vaccine is given at 4½/2-5 years to ensure protection during school years. Without this booster it is unlikely that any three dose schedule of primary immunisation would provide immunity until school leaving.
It was reassuring that no child had antitoxin concentrations below the minimum protective level of tetanus or diphtheria of0 01 IU/ml.'2 For individual protection against diphtheria, however, a higher level of 0 1 IU/ ml is desirable.'3 The few children with diphtheria antitoxin concentration below 0-1 IU/ml were not clustered in the accelerated schedule group. Among the children who did not receive a diphtheria/tetanus booster, there was no evidence that those immunised at an accelerated schedule had a significantly lower diphtheria or tetanus antitoxin concentration than those who had received a longer schedule. There is no obvious explanation for the finding that those who received their third dose of triple vaccine before 6 months had a significantly higher tetanus antitoxin concentration than those who received it between 6 and 7 months of age.
As may be expected, the antitoxin concentrations to diphtheria and tetanus were highest in the group who had received the 18 month diphtheria/tetanus booster. However, these children may also be at greater risk of local reactions to a preschool booster. 14 Double blind trials of pertussis vaccines in the 1940s established a vaccine efficacy of 78% and found no evidence of waning protection during the two year follow up. 15 Evidence from studies of combined diphtheria/tetanus/pertussis vaccine after licensing implied that the 3, 4½/2-5, and 8½/2-11 month schedule of immunisation was effective in preventing notified disease for up to 3 years.'6-'8 Although no antibody correlate of protection for whooping cough has been established, the finding that antibody titres to three pertussis antigens were similar in children who completed immunisation before the age of 6 months compared with those who completed it after 8 months of age is reassuring.
Schedules of primary immunisation aim at combining the advantage of providing early protection against whooping cough with adequate longlasting protection against diphtheria and tetanus. In the United Kingdom in the early 1960s an accelerated schedule with three doses of triple vaccine before 6 months of age and a further dose at 18 months was recommended.'9 Subsequently, concern over low attendance rates for the booster led to the abandonment of the fourth dose and a lengthening of the intervals between the first three doses. This decision was made despite the observation that infants were more likely to attend clinics in the early months of life.' Recent The inclusion criteria for patients were: a score on the clinical dementia rating scale of more than 0 5"'; a score on the short portable mental status questionnaire of less than 20 (out of 30)"; a score of seven or less on the Hachinski scale'2; no evidence of abnormalities on computed tomography other than cerebral atrophy; and no evidence of focal dysfunction on electroencephalography. For each patient, a control matched for age (within five years) and sex was selected randomly from the population registry of the municipality where the patient lived.
Based on patients' family history of dementia
